Latest Earnings Results: Q2 '26
Estimated EPS
$6.01
Reported EPS
$8.38
Surprise
+39.53%
Estimated Rev
$20.69B
Reported Rev
$22.97B
Surprise
+11.07%
• Reported GAAP EPS of $7.94 up 26.03% YoY • Reported revenue of $22.97B up 47.67% YoY • Eli Lilly and Company raised its 2026 full-year revenue guidance to $85.0 billion to $87.0 billion, with non-GAAP EPS guidance updated to a range of $35.50 to $36.50 per share.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $9.85 | -- | -- | N/A |
Q2 '26 | $6.01 | $8.38 | 39.53% | BEAT |
Q1 '26 | $6.97 | $8.55 | 22.71% | BEAT |
Q4 '25 | $6.91 | $7.54 | 9.10% | BEAT |
Q3 '25 | $5.69 | $7.02 | 23.33% | BEAT |